Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Corticobasal Degeneration

Neurological & Neuromuscular

Corticobasal Degeneration (CBD) Clinical Trials

Also called CBD, corticobasal ganglionic degeneration, asymmetric rigidity

Corticobasal degeneration (CBD) is a rare atypical parkinsonian disorder characterized by progressive asymmetric motor dysfunction and cognitive decline resulting from tau protein accumulation in cortical and subcortical structures. Pathologically, the disease is defined by tau pathology with regional variation in affected brain regions.

In plain words, corticobasal degeneration is a rare brain disease where a protein called tau builds up and harms brain cells. Stiffness and clumsiness often start in one arm or leg, and thinking, speech and swallowing slowly become harder.

Get an email when new Corticobasal Degeneration trials open or the FDA decides. Get alerts

Corticobasal Degeneration

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 14 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Corticobasal Degeneration yet.

Corticobasal Degeneration has no FDA-approved medicines, 15 open or active clinical trials (12 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Corticobasal Degeneration

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Corticobasal Degeneration

Clinically, patients present with asymmetric rigidity, bradykinesia, and dystonia, often affecting one limb preferentially (the affected limb becomes progressively more stiff and difficult to control). Distinctive cortical features include sensory loss, apraxia (inability to perform learned purposeful movements despite intact motor function), and the alien limb phenomenon (sensation that a limb is not under voluntary control and acts independently).

Keep reading about Corticobasal Degeneration

Cognitive decline is gradual but progressive, affecting executive function, judgment, and planning. Progressive gait disturbance and postural instability develop, with variable impact on ambulatory function. Speech difficulties including dysarthria and progressive loss of verbal output occur as disease advances. Like PSP, response to levodopa is typically poor or absent, a key diagnostic feature. Brain MRI may show asymmetric cortical atrophy.

What are the symptoms of Corticobasal Degeneration?

These are common symptoms of Corticobasal Degeneration, and how strong they are varies from person to person.

  • Asymmetric parkinsonism with rigidity and bradykinesia
  • Dystonia affecting affected limb
  • Cortical sensory loss and apraxia
  • Alien limb phenomenon
  • Progressive cognitive decline
  • Speech and swallowing difficulties

Who gets Corticobasal Degeneration?

Corticobasal degeneration typically presents between ages 50-70 years, with an average onset age of 64 with variable age of onset within this range. The condition affects males and females equally. Sporadic occurrence is most common, with rare familial cases reported. No ethnic predilection is evident, and CBD occurs across all populations.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

How to get help paying for Corticobasal Degeneration treatment

Charity funds and drugmaker programs for Corticobasal Degeneration, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · CurePSP
    Quality of Life Respite Program fund
    Open

    Pays for: In-home respite care hours for caregivers.

    The foundation says: “The Quality of Life Respite Program is now accepting applications on a rolling basis as of August 2025.”
Status as each foundation showed it on November 16, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Corticobasal Degeneration

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Corticobasal Degeneration resources

Reputable organizations and medical references for learning more about Corticobasal Degeneration, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Corticobasal Degeneration

Use this Corticobasal Degeneration clinical trial finder to see the 12 studies recruiting patients and 3 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 5 test a treatment and 10 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

15 active trials worldwide
Filter:
Sort:
Not yet recruitingObservational study, no treatment givenRecently updatedNCT07569367

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

Sponsor: BioSensics

The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine,...

Ages 40 Years+2 locations
Expected to start Nov 2026Updated 1 month agoEst. Aug 2030 (~3y 9m)
Not yet recruitingTreatment trialPhase 2Recently updatedNCT07868328

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

Intervention: NIO752, Placebo

Sponsor: Novartis Pharmaceuticals

This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies. Eligible participants will be randomized to receive either NIO752 or placebo during the double-blind treatment period followed by an Open-label Extension (OLE).

Ages 41 Years to 81 Years
Expected to start Oct 2026Updated 1 month agoEst. Mar 2029 (~2y 4m)
RecruitingObservational study, no treatment givenRecently updatedNCT04363684

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Sponsor: Mayo Clinic

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Ages 18 Years+
Started Mar 2020Updated 1 month agoEst. Aug 2030 (~3y 9m)
RecruitingTreatment trialRecently updatedNCT07844655

Wellness in PSP and CBD

Intervention: Exercise and Peer Support

Sponsor: Silke Cresswell

The goal of this interventional study is to evaluate the feasiblity and effectiveness of a multimodal lifestyle program for individuals living with Progressive Supranuclear Palsy or Corticobasal Deneration. The main objectivess of the study are to:

Ages 19 Years+1 location
Started Apr 2026Updated 1 month agoEst. Dec 2027 (~1y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT07805967

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

Intervention: We did not apply any interventions; only observational research was conducted.

Sponsor: Second Affiliated Hospital of Soochow University

This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establi...

Ages 18 Years+
Started Nov 2025Updated 2 months agoEst. Aug 2030 (~3y 9m)
Find Corticobasal Degeneration trials near you, ranked by distance →
Active trial locations25 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+17 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Corticobasal Degeneration trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Corticobasal Degeneration foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Corticobasal Degeneration patient communities

Facebook groups, Reddit communities and YouTube channels where Corticobasal Degeneration patients, caregivers and advocacy groups talk.

Companies developing Corticobasal Degeneration treatments

Drugmakers that list Corticobasal Degeneration in their rare disease portfolio, 2 in all.

Questions people ask about Corticobasal Degeneration